# Domain-Specific AI Models: Why General-Purpose LLMs Fail in High-Stakes Workflows

## The Problem: General-Purpose Models Hit a Wall in Specialized Domains

You point a general-purpose LLM at a drug discovery pipeline or a binary vulnerability analysis. It generates plausible-sounding text. **But plausible isn't useful when the stakes are a 10-year drug trial or a zero-day exploit.**

Here's what actually breaks:

- **Life sciences:** Drug development takes 10–15 years from target discovery to approval. Most time is burned in early stages — figuring out what's worth testing. A general model can summarize papers but **can't synthesize evidence across molecular, genomic, and pathway data** to generate testable hypotheses
- **Cybersecurity:** Defenders need to analyze compiled binaries, trace vulnerability chains, and investigate threats. General models refuse to engage with exploit patterns — **safety guardrails designed for consumers block legitimate security work**
- **Multi-step research workflows:** Real research isn't one question → one answer. It's: query a database → interpret results → cross-reference literature → design an experiment → iterate. General models **can't orchestrate across 50+ specialized tools and data sources**
- **Accuracy thresholds:** In biology, a hallucinated protein interaction or a wrong gene pathway doesn't just waste time — it sends a team down a months-long dead end

**The hidden cost:** $17 billion has been invested in AI-driven drug discovery since 2019. Zero AI-developed drugs have reached large-scale trials. The models aren't the bottleneck — **the integration with real scientific workflows is.**

## Why This Happens

- General-purpose models optimize for **breadth over domain depth** — they know something about everything but lack the reasoning chains specific to molecular biology or binary analysis
- Safety guardrails are **one-size-fits-all** — what protects a consumer from harmful output also prevents a security researcher from analyzing malware behavior
- Tool integration is an afterthought — models generate text, but real workflows require **querying databases, running analyses, interpreting structured data, and chaining results**
- Researchers need the model to **move a project forward**, not just answer questions — that requires agentic behavior across multi-step processes

**Ask yourself:** If your model can't connect to the actual databases, tools, and data sources where domain knowledge lives, is it really helping — or just generating sophisticated summaries?

## The Mental Model Shift

> **Stop treating AI as a question-answering system. Start treating it as a domain-specific research orchestrator.**

- **Old:** Model answers questions about biology → researcher does the actual work
- **New:** Model synthesizes evidence, queries databases, generates hypotheses, plans experiments → researcher validates and steers
- **Old:** One model serves all domains with the same guardrails
- **New:** Specialized models with **domain-appropriate access controls** — relaxed for verified professionals, restricted for everyone else

## What Happens If You Ignore This

- **Pharma team uses a general model for target identification** → it suggests plausible but unsupported gene-disease associations → team spends 6 months on a dead-end target → millions wasted before the first experiment
- **Security team needs to analyze a compiled binary for vulnerabilities** → general model refuses to discuss exploit patterns → team falls back to manual reverse engineering → the vulnerability ships to production while they're still analyzing it
- **Research lab tries to chain multiple tools through a general model** → model hallucinates API calls, misinterprets database outputs, loses context between steps → researchers spend more time fixing the AI's mistakes than doing actual science

## The Approach: Domain-Specialized Models + Controlled Access

The pattern emerging across both life sciences and cybersecurity is the same:

1. **Optimize reasoning for the domain** — train on domain-specific data, benchmark against domain-specific tasks (not general benchmarks)
2. **Integrate tools natively** — connect the model to the actual databases, analysis tools, and data sources professionals use
3. **Adjust guardrails per audience** — verified security professionals get relaxed restrictions; general users don't
4. **Control access through identity verification** — not open release, not closed to five partners, but **tiered access with governance**

## The Solution: What This Architecture Looks Like

| Aspect | General-Purpose Model | Domain-Specific Model |
|---|---|---|
| Reasoning | Broad, shallow across all domains | Deep chains across molecules, genes, pathways (or binaries, exploits, threats) |
| Tool access | Text in, text out | Orchestrates 50+ specialized databases and analysis tools |
| Safety guardrails | One-size-fits-all restrictions | Domain-appropriate — relaxed for verified professionals |
| Deployment | Open to everyone | Tiered access with identity verification and governance |
| Output | Answers and summaries | Hypotheses, experiment plans, vulnerability reports — **actionable artifacts** |
| Benchmark performance | Good on general tasks | 95th percentile of human experts on domain-specific prediction tasks |

Key architectural decisions:

- **Orchestration layer over specialized tools** — the model doesn't replace databases, it connects them. A life sciences plugin connecting to multi-omics databases, literature repos, and protein structure tools
- **Agentic SDK for developers** — sandboxed execution, configurable memory, built-in orchestration so teams can build domain agents without managing infrastructure
- **Trusted access programs** — organizations prove beneficial use, maintain safeguards, restrict access to approved users. This is the security boundary that makes domain relaxation possible

The trade-off is real: tighter ecosystem integration means **vendor lock-in**. Teams that want provider-agnostic architectures may resist. But the alternative — stitching together general models with custom tool chains — is exactly the integration gap that's kept AI from delivering real results in high-stakes domains.

## The Question to Sit With

$17 billion invested, zero AI-developed drugs in large-scale trials. The models have been "good enough" at language for years. **If the bottleneck was never the model's intelligence but its inability to operate inside real workflows — how many other domains are stuck in the same gap between "impressive demo" and "actually useful"?**
